Pharmacy and Therapeutics Committee Agenda for March 30, 2006
The Pharmacy & Therapeutics Committee will meet Thursday, March 30, 2006, from 8:45 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.
Agenda Items:
1. Proposal: Identification of preferred drugs in the therapeutic class Intranasal Steroids
Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Beconase AQ (beclomethasone dipropionate), Flonase (fluticasone propionate), flunisolide, Nasacort AQ (triamcinolone acetonide), Nasarel (flunisolide), Nasonex (mometasone furoate), Rhinocort Aqua (budesonide)
2. Proposal: Identification of preferred drugs in the therapeutic class Calcitonins
Description: Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Fortical (calcitonin-salmon), Miacalcin (calcitonin-salmon)
3. Proposal: Identification of preferred drugs in the therapeutic class HMG-CoA Reductase Inhibitors (Statins)
Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Advicor (lovastatin/niacin extended-release), Altoprev (lovastatin extended-release), Caduet (atorvastatin/amlodipine), Crestor (rosuvastatin), Lescol (fluvastatin), Lescol XL (fluvastatin XL), Lipitor (atorvastatin), lovastatin, Mevacor (lovastatin), Pravachol (pravastatin), Pravigard PAC (pravastatin/buffered aspirin), Vytorin (simvastatin/ezetimibe), Zocor (simvastatin)
4. Proposal: Identification of preferred drugs in the therapeutic class Triglyceride Lowering Agents
Description: Description: The Committee will review the following drugs to determine preferred and non-preferred status.
Drugs Affected: Antara (fenofibrate), fenofibrate, gemfibrozil, Lofibra (fenofibrate), Lopid (gemfibrozil), Omacor (Omega-3 acid ethyl esters), Tricor (fenofibrate), Triglide (fenofibrate)
8:45 AM | 9:00 AM | Welcome and Introductions |
9:00 AM | 10:00 AM | Comments from Interested Parties* |
10:00 PM | 10:45 PM | Clinical Review of Intranasal Steroids |
10:45 PM | 11:15 PM | Clinical Review of Calcitonins |
11:15 PM | 12:15 PM | Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information) |
12:15 PM | 12:30 PM | Final Recommendations for preferred drugs (Calcitonins and Intranasal Steroids) |
12:30 AM | 1:30 PM | Clinical Review of HMG-CoA Reductase Inhibitors (Statins) |
1:30 PM | 2:15 PM | Clinical Review of Triglyceride Lowering Agents |
2:15 PM | 2:45 PM | Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information) |
2:45 PM | 2:55 PM | Final Recommendations for preferred drugs (Statins and Triglyceride Lowering Agents) |
2:55 PM | 3:00 PM | Final Comments and Adjournment |
*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit a clinical study or clinical report, rather than comments, must submit the study at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review of this type of material. If such material is submitted after this time, it cannot be considered by the Committee.